Article thumbnail

Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats

By Allen Clermont, Tamie J. Chilcote, Takeshi Kita, Jia Liu, Priscilla Riva, Sukanto Sinha and Edward P. Feener
Topics: Complications
Publisher: American Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:3292335
Provided by: PubMed Central

Suggested articles

Citations

  1. AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.
  2. (1999). and molecular investigations of renal kallikrein-kinin system in diabetic rats.
  3. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats.
  4. Bradykinin relaxation in small porcine retinal arterioles.
  5. (2006). Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost
  6. (2007). Changes in plasma prekallikrein activity, blood pressure, and left ventricular thickness in hypertensive and normotensive diabetic rats. Methods Find Exp Clin Pharmacol
  7. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy.
  8. (2011). Correlation between spectral domain optical coherence tomography findings and fluorescein angiography patterns in diabetic macular edema.
  9. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
  10. Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat.
  11. Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs.
  12. (2005). Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist. Regul Pept
  13. (1996). Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res
  14. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
  15. (2005). Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol
  16. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.
  17. High molecular weight kininogen binds to laminin: characterization and kinetic analysis.
  18. (1999). High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care
  19. Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser doppler velocimetry study.
  20. (2004). Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the aminoterminal domain of C1-inhibitor. Thromb Haemost
  21. JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease.
  22. Management of diabetic retinopathy: a systematic review.
  23. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.
  24. Plasma kallikrein and diabetic macular edema.
  25. (2009). Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension
  26. Plasma prekallikrein as a risk factor for diabetic retinopathy.
  27. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.
  28. (1999). Progression to proliferative retinopathy and macular oedema requiring treatment: assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol Scand
  29. (2000). Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons. Invest Ophthalmol Vis Sci
  30. Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome.
  31. Reduced retinal blood flow velocity in diabetic retinopathy.
  32. Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors.
  33. Sensitive blood-retinal barrier breakdown quantitation using Evans blue.
  34. (1997). Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci
  35. Studies on the interaction between collagen and a plasma kallikrein-like activity. Evidence for a surface-active enzyme system.
  36. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically signifi-cant diabetic macular edema.
  37. The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney.
  38. (1998). The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.
  39. (1997). Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective b-isoform-selective inhibitor. Diabetes

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.